Preclinical investigations

Lung cancer
#Immunotherapy #Lung cancer #Oncology #Preclinical investigations #The Francis Crick Institute

Triple combination treatment shrinks lung cancer tumours in mice

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments in mice with lung cancer allow immunotherapies to target non-responsive tumours. Their findings show that targeting tumours in different ways simultaneously might increase response to treatments. Read More

#Editor's Choice #News

Neurons
#Aberdeen University #Durham University #Neurodegenerative disorders #Neuroscience #Nevrargenics #Preclinical investigations

Novel drug reduces neuronal death in neurodegenerative disease

New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. The peer reviewed study published in Frontiers in Neuroscience was conducted by academics at Aberdeen and… Read More

#News

Fibroblast growth factor receptor 3
#Events #Gene mutation #Preclinical investigations #Tyra Biosciences

Preclinical tests support FGFR3 inhibitor in skeletal dysplasia

Biotechnology company Tyra Biosciences has announced preclinical proof-of-concept results with TYRA-300, an investigational oral fibroblast growth factor receptor 3 (FGFR3) selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024). HCH is a… Read More

#News

Conference speaker
#ASCO #Clinical trials #Drug discovery #Events #Oncology #Preclinical investigations

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More

#Cancer Research #News #Trending News

Woman using an asthma inhaler
#Asthma #CAR-T #Cell therapy #China #Preclinical investigations

Researchers push asthma into remission with one dose of CAR-T

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study. The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was… Read More

#Editor's Choice #News

#Atrogi #Obesity #Preclinical investigations #Stockholm University #Weight loss

Dual receptor beta-agonist promotes healthy weight loss

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. ATR-127… Read More

#News

Petri dish used for bacterial research
#Bacteria #Endothelial dysfunction #Preclinical investigations #Sepsis #University of Queensland

New drug could prevent sepsis-related organ failure

A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient’s blood vessels. Researchers from The University of Queensland and the Queensland Children’s Hospital (QCH) have successfully tested the first-in-class drug in mice. Dr Mark Coulthard from UQ… Read More

#News

Knee x-ray
#Bone disease #Peptides #Preclinical investigations #University of Birmingham

Peptide shows promise as therapeutic for bone loss disorders

Researchers have shown that a naturally occurring peptide holds promise as a new therapeutic for bone loss disorders and could have advantages over existing drugs. PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was first identified in 2015 by University of Birmingham researchers. The latest research… Read More

#News

Mouse in laboratory
#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Case Study: Streamline preclinical drug discovery

A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More

#News

#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Streamline preclinical drug discovery: PBMC-humanised mouse models

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More

#Resources

#ADME / Tox #Cell Science #Organoids #Preclinical development #Preclinical investigations #Toxicology

Beyond animal testing: The rise of organoids in toxicology research

Around 30% of drugs show adverse reactions during human clinical trials despite promising pre-clinical studies. One of the major causes of the high attrition rate is the poor predictive value of current preclinical models used in drug development. Traditional 2D cell cultures often fail to replicate the cellular… Read More

#News

Neuroscience
#Autism #Gate Neurosciences #Neurodevelopmental disorders #Neuroscience #Preclinical investigations

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More

#News

CT scans of the brain
#Alzheimer's #Galimedix Therapeutics #Neurodegenerative disorders #Neuroscience #Preclinical investigations

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et. al. 2022). Read More

#News #Trending News

Cardiovascular system
#Cardiovascular disease #Immunology / Virology & Vaccines #Preclinical investigations #Vaxxinity

Vaccine successfully lowers cholesterol in preclinical studies

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. VXX-401 is a synthetic… Read More

#News

Tau proteins
#Alzheimer's #Gene therapy #Preclinical investigations #Tau protein #Voyager Therapeutics

New data validates tau silencing gene therapy for Alzheimer’s

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy programme will be presented at the upcoming 2024 International Conference on Alzheimer’s and… Read More

#Editor's Choice #News

Kidney on a chip technology
#Kidney disease #Organ-on-a-chip #Organoids #Preclinical investigations #University of Washington

Kidney platforms could reduce animal testing in tox studies

Kidney disease researchers at the University of Washington will use a multimillion-dollar federal grant to advance drug development platforms that would reduce reliance on animal tests. The investigators, in the UW schools of Medicine and Pharmacy, received the $7.3 million award from the National Center for… Read More

#News